Homology Medicines Insiders
FIXXDelisted Stock | USD 1.09 0.06 5.83% |
Homology Medicines employs about 7 people. The company is managed by 10 executives with a total tenure of roughly 8 years, averaging almost 0.0 years of service per executive, having 0.7 employees per reported executive. Break down of Homology Medicines' management performance can provide insight into the company performance.
Homology |
Homology Medicines Management Team Effectiveness
The company has return on total asset (ROA) of (0.364) % which means that it has lost $0.364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9002) %, meaning that it created substantial loss on money invested by shareholders. Homology Medicines' management efficiency ratios could be used to measure how well Homology Medicines manages its routine affairs as well as how well it operates its assets and liabilities.Homology Medicines Workforce Comparison
Homology Medicines is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,026. Homology Medicines maintains roughly 7.0 in number of employees contributing less than 1% to equities under Health Care industry.
Homology Medicines Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Homology Medicines insiders, such as employees or executives, is commonly permitted as long as it does not rely on Homology Medicines' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Homology Medicines insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Arthur Tzianabos over six months ago Exercise or conversion by Arthur Tzianabos of 14280 shares of Homology Medicines subject to Rule 16b-3 | ||
Arthur Tzianabos over a year ago Sale by Arthur Tzianabos of 10616 shares of Homology Medicines | ||
Smith W Bradford over a year ago Acquisition by Smith W Bradford of 213000 shares of Homology Medicines subject to Rule 16b-3 |
Homology Medicines Notable Stakeholders
A Homology Medicines stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Homology Medicines often face trade-offs trying to please all of them. Homology Medicines' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Homology Medicines' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Paul JD | President COO | Profile | |
Michael MBA | Chief Officer | Profile | |
Melissa Gelormini | Senior Resources | Profile | |
Saswati Chatterjee | CoFounder Board | Profile | |
CPA Michaud | Corporate Finance | Profile | |
Deborah Kinch | Chief Officer | Profile | |
Julie MD | Sr Operations | Profile | |
Theresa McNeely | Chief Advocate | Profile | |
Cara Mayfield | Director Communications | Profile | |
Albert Seymour | Chief Scientific Officer | Profile |
About Homology Medicines Management Performance
The success or failure of an entity such as Homology Medicines often depends on how effective the management is. Homology Medicines management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Homology management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Homology management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts. Homology Medicines operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 224 people.
Please note, the imprecision that can be found in Homology Medicines' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Homology Medicines. Check Homology Medicines' Beneish M Score to see the likelihood of Homology Medicines' management manipulating its earnings.
Homology Medicines Workforce Analysis
Traditionally, organizations such as Homology Medicines use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Homology Medicines within its industry.Homology Medicines Manpower Efficiency
Return on Homology Medicines Manpower
Revenue Per Employee | 165.1K | |
Revenue Per Executive | 115.6K | |
Net Loss Per Employee | 16.1M | |
Net Loss Per Executive | 11.3M | |
Working Capital Per Employee | 10.3M | |
Working Capital Per Executive | 7.2M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Homology Stock
If you are still planning to invest in Homology Medicines check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Homology Medicines' history and understand the potential risks before investing.
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |